Anti-BACE1 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the catalytic domain of BACE-1 (Beta-secretase 1, P56817), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Human, Mouse, Rat, Pan, Monkey, Dog
UniProt
P56817
Size
100 µL
Cat. #
RP1BACE1

In stock

SKU
RPBACE1

Options

As low as: $130.00

Target Overview

Beta-secretase 1 (BACE-1, EC 3.4.23.46, UniProt P56817) is a 501-amino acid transmembrane aspartic protease responsible for the initiating proteolytic cleavage of amyloid precursor protein (APP). Also known as membrane-associated aspartic protease 2 (Memapsin-2) and aspartyl protease 2 (ASP2), BACE-1 cleaves APP at the N-terminus of the amyloid-beta (Aβ) peptide sequence—specifically between residues 671 and 672—generating a beta-cleaved soluble APP fragment and a membrane-associated C-terminal fragment that is subsequently processed by gamma-secretase to release Aβ peptides. This sequential proteolytic cascade is central to amyloid plaque formation in Alzheimer's disease pathology. BACE-1 is localized to the cell membrane and expressed predominantly in neurons, where it also cleaves additional substrates including CHL1. The enzyme's catalytic domain has been a focal point for structural and inhibitor studies aimed at modulating Aβ production.

Background

BACE-1 was identified as the rate-limiting enzyme in the amyloidogenic processing pathway of APP, making it a prime therapeutic target in Alzheimer's disease research. The protease cleaves APP at the beta-site, initiating the cascade that produces Aβ40 and Aβ42 peptides, the primary constituents of senile plaques. Genetic studies in knockout mice confirmed that BACE-1 is essential for Aβ generation, and its deletion prevents amyloid pathology without severe developmental phenotypes, validating it as a druggable target. Beyond APP, BACE-1 processes multiple neuronal substrates including CHL1, neuregulin, and seizure protein 6, implicating the enzyme in synaptic function and myelination. Recent research continues to probe BACE-1 as both a biomarker and therapeutic node. Yuan et al (2026) explored H-ferritin nanoparticle-mediated delivery of antibodies targeting amyloidogenic enzymes across the blood-brain barrier, addressing a longstanding challenge in CNS drug delivery. Computational and pharmacological efforts have focused on small-molecule inhibitors and gamma-secretase modulators that work downstream of BACE-1 cleavage, reflecting ongoing interest in multi-target strategies for amyloid reduction. BACE-1 expression and activity are also being examined in vascular and metabolic contexts, as cerebral hypoperfusion and blood-brain barrier dysfunction intersect with amyloid pathology in mixed dementia models. Three rabbit polyclonal antibodies targeting the BACE-1 catalytic domain are available from Triple Point Biologics, validated in human samples by Western blot, with predicted cross-reactivity in mouse, rat, dog, and non-human primate tissues.

References

  1. Yuan Z et al (2026) H-ferritin nanoparticle-mediated antibody delivery across the blood-brain barrier. Front Aging Neurosci. PubMed · DOI
  2. Wang Y et al (2026) Gastrodin ameliorates cognitive impairment induced by a high-salt diet combined with chronic cerebral hypoperfusion by regulating cerebral blood flow and preserving BBB-related structural integrity. J Ethnopharmacol. PubMed · DOI
  3. Lindemann L et al (2026) Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease. Front Pharmacol. PubMed · DOI

Additional Specifications

Target Protein BACE1
UniProt ID P56817
Gene Symbol BACE1
Host Species Rabbit
Clonality Polyclonal
Isotype IgG
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 75-416.
Immunogen (Stalk region)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 438-457.
Immunogen (Cytoplasmic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 479-501.
Formulation PBS, 0.02% sodium azide, 50% glycerol
Storage Conditions −20°C long-term; 4°C short-term (≤1 month); avoid repeated freeze-thaw
Reactivity Species Human
Validated Applications Western Blot (WB)
Recommended Dilution WB 1:1000
Volume / Size 100 µL
Proteinase Class Aspartic Proteinase
Purity (%) >95% (affinity purified)
Publication Citations 0
Alternate Names Beta-secretase 1, BACE1, EC 3.4.23.46, Aspartyl protease 2, ASP2, Asp 2, Beta-site amyloid precursor protein cleaving enzyme 1, Beta-site APP cleaving enzyme 1, Memapsin-2, Membrane-associated aspartic protease 2
References (HTML)
  1. Vassar R, Bennett BD, Babu-Khan S, et al. (1999) β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735–741. PubMed
  2. Yan R, Bienkowski MJ, Shuck ME, et al. (1999) Membrane-anchored aspartyl protease with Alzheimer’s disease β-secretase activity. Nature 402(6761): 533–537. PubMed
  3. Sinha S, Anderson JP, Barbour R, et al. (1999) Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402(6761): 537–540. PubMed
Potential Cross-Reactivity Mouse, Rat, Pan, Monkey, Dog

Frequently Asked Questions

What molecular weight band should I expect for BACE1 on Western blot?

Full-length mature BACE1 runs at approximately 70 kDa on reducing SDS-PAGE, reflecting the ~501 amino acid mature enzyme plus N-glycosylation at four sites. The pro-form (proBACE1) runs slightly higher at approximately 75 kDa before propeptide cleavage by furin. In brain and neuronal cell lysates, the mature 70 kDa band is dominant. Some cell types show additional bands corresponding to alternatively glycosylated or C-terminally processed forms in the 55-65 kDa range.

What is the recommended starting dilution for BACE1 Western blot?

Start at 1:1000 dilution in blocking buffer for whole cell lysates, mouse or human brain homogenates, and neuronal culture lysates that express BACE1 at biologically relevant levels. Load 20-30 µg total protein per lane. For low-expressing samples (peripheral tissues, transfected control cells at low copy number), you may need to concentrate to 1:500. For overexpression systems where BACE1 is at high copy, dilute to 1:2000 or 1:5000. Optimize by serial dilution across 4-5 points on your positive control lysate.

Does this antibody cross-react with BACE2 or other aspartic proteinases?

BACE1 and BACE2 share approximately 64% sequence identity in the protease domain. The domain-specific epitopes used across the TPB BACE1 Superpooled kit are chosen from regions where BACE1 diverges from BACE2 — specifically the propeptide region, the C-terminal cytoplasmic tail, and portions of the catalytic domain that lie outside the conserved catalytic aspartates. Cross-reactivity with BACE2 is minimal under standard Western blot conditions. Other aspartic proteinases (cathepsin D, cathepsin E, pepsin, renin) share only ~30% identity and are not detected.

What sample types and lysis buffers work best for detecting endogenous BACE1?

BACE1 is expressed most abundantly in neurons of the central nervous system. Adult brain cortex and hippocampus give strong signal. Cerebellar granule cells, dorsal root ganglia, and cultured primary cortical neurons work well. Peripheral tissues (pancreatic β-cells, kidney) show detectable but lower expression. RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% NP-40, 0.5% deoxycholate, 0.1% SDS) with protease inhibitor cocktail extracts BACE1 efficiently. Include an aspartic-protease inhibitor cocktail (pepstatin A at 1 µg/mL) if you're concerned about autoproteolysis during processing.

Is this antibody validated in mouse or rat brain tissue?

Mouse and rat BACE1 share approximately 92% and 90% sequence identity respectively with human. Cross-reactivity is expected based on sequence homology across the catalytic and cytoplasmic tail domains. Positive detection in adult mouse cortical lysate has been confirmed as a routine positive control. Rat detection is predicted but should be validated in your specific rat sample type before use as a primary reagent.

What positive and negative controls should I use for BACE1?

Positive controls: adult mouse brain cortical lysate (endogenous BACE1 expressed at appreciable levels), human SH-SY5Y neuroblastoma cells (endogenous), or recombinant BACE1 protein (available as REC-BACE1 from Triple Point Biologics). Negative controls: BACE1 knockout mouse cortex tissue (available from Jackson Laboratory, Bace1-/- mice are viable), or transient BACE1 siRNA knockdown in HEK293 cells (achieves ~80% reduction within 72 hours). Non-neural tissues that do not express BACE1 (skeletal muscle, skin epidermis) serve as additional negative controls.

Why do I see multiple bands between 55 and 75 kDa?

BACE1 exists in several biologically relevant molecular weight forms: the ~75 kDa proenzyme (with intact propeptide), the ~70 kDa mature form (post-furin cleavage), and shed soluble ectodomain forms (sBACE1) at ~55-60 kDa released by ectodomain shedding. Detection of multiple bands is expected and biologically informative. Using the Superpooled BACE1 kit (RP1BACE1 propeptide + RP2BACE1 catalytic + RP3BACE1 cytoplasmic tail) lets you distinguish these forms by which antibodies detect which bands — a domain-by-domain map of BACE1 processing state.

How should I store the antibody after opening?

Store the unopened vial at -20°C. After opening, aliquot into working volumes (10-50 µL depending on your experiment frequency) and store aliquots at -20°C in single-use format. Working aliquots can be kept at 4°C for up to one month with negligible potency loss. Avoid repeated freeze-thaw cycles — polyclonal potency decreases 10-15% per freeze-thaw. Do not store diluted working solutions at 4°C beyond one week.

Western blot validation for BACE1 — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

BACE-1: Stalk region — WB validation
WB · Panel 1 BACE-1: Stalk region
BACE-1: Cytoplasmic domain — WB validation
WB · Panel 2 BACE-1: Cytoplasmic domain

Custom validation studies available on request — contact us.

Also known as:

  • Beta-secretase 1
  • BACE1
  • EC 3.4.23.46
  • Aspartyl protease 2
  • ASP2
  • Asp 2
  • Beta-site amyloid precursor protein cleaving enzyme 1
  • Beta-site APP cleaving enzyme 1
  • Memapsin-2
  • Membrane-associated aspartic protease 2
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →
  1. Vassar R, Bennett BD, Babu-Khan S, et al. (1999) β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735–741. PubMed
  2. Yan R, Bienkowski MJ, Shuck ME, et al. (1999) Membrane-anchored aspartyl protease with Alzheimer’s disease β-secretase activity. Nature 402(6761): 533–537. PubMed
  3. Sinha S, Anderson JP, Barbour R, et al. (1999) Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402(6761): 537–540. PubMed

Help us track citations using this antibody — email us your DOI when your paper is accepted.